<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03990051</url>
  </required_header>
  <id_info>
    <org_study_id>oGvHD-1</org_study_id>
    <nct_id>NCT03990051</nct_id>
  </id_info>
  <brief_title>Treatment Safety and Efficacy of Pro-ocular™ 1% for Chronic Ocular Graft Following Allogeneic HSCT.</brief_title>
  <official_title>Treatment Safety and Efficacy Using Pro-ocular™ 1% for Chronic Ocular Graft-versus-host Disease (GvHD) Following Allogeneic Hematopoietic Stem Cell Transplantation.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Glia, LLC</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>ORA, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Glia, LLC</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To evaluate the safety and efficacy of Pro-ocular™ 1% topical gel administered twice daily&#xD;
      for 70 days in reducing or eliminating symptoms and signs of chronic ocular GvHD.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Ocular graft versus host disease presents a most severe form of ocular surface disease that&#xD;
      compromises quality of life of afflicted allogeneic hematopoietic transplantation patients.&#xD;
&#xD;
      A controlled study is necessary to verify findings obtained to date in isolated patients.&#xD;
      Currently available ophthalmic solutions and suspensions, drugs and devices largely have not&#xD;
      been effective in alleviating the suffering of chronic ocular GvHD patients. Thus, this is an&#xD;
      unmet need that Pro-ocular™ topical gel can fulfill.&#xD;
&#xD;
      Potential benefits: Decrease or cessation of adverse ocular symptoms and signs of chronic&#xD;
      ocular GvHD, reduction or elimination of the need for other topical ocular therapeutic&#xD;
      treatments for chronic ocular GvHD, and restoration of quality of life.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">October 17, 2019</start_date>
  <completion_date type="Anticipated">November 19, 2021</completion_date>
  <primary_completion_date type="Anticipated">October 31, 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>The double-masked phase involves placebo controlled administration of study drug for 70 days or 10 weeks. Subsequently the placebo group will receive the active study drug of 42 days or 6 weeks. Long term open label phase to 27 months.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
    <masking_description>Randomized double-masked parallel treatment assignment will be made using a block design at the ratio of 2:1, study drug:placebo, (22 subjects:11 subjects). This 70-day double-masked phase will be followed by 6 weeks open-label active drug treatment of the subjects previously on placebo.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Ocular pain from Glia OSD Symptoms Questionnaire</measure>
    <time_frame>1 hour</time_frame>
    <description>Change in ocular pain score</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Ocular discomfort</measure>
    <time_frame>1 hour</time_frame>
    <description>Change in ocular discomfort score</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Ocular discomfort</measure>
    <time_frame>2 weeks</time_frame>
    <description>Change in ocular discomfort score</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Corneal fluorescein staining</measure>
    <time_frame>10 weeks</time_frame>
    <description>Change in fluorescein staining score</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Conjunctival staining</measure>
    <time_frame>10 weeks</time_frame>
    <description>Change in conjunctival staining score</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Modified SANDE</measure>
    <time_frame>2 weeks</time_frame>
    <description>Change in SANDE score</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Modified SANDE</measure>
    <time_frame>6, 10 weeks</time_frame>
    <description>Change in SANDE score</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Modified SANDE</measure>
    <time_frame>10 weeks</time_frame>
    <description>Change in SANDE score</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Glia OSD Symptoms Questionnaire</measure>
    <time_frame>1 hour</time_frame>
    <description>Change in total score</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Glia OSD Symptoms Questionnaire</measure>
    <time_frame>2 weeks</time_frame>
    <description>Change in total score</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Glia OSD Symptoms Questionnaire</measure>
    <time_frame>6 weeks</time_frame>
    <description>Change in total score</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Glia OSD Symptoms Questionnaire</measure>
    <time_frame>10 weeks</time_frame>
    <description>Change in total score</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tear Film</measure>
    <time_frame>1 hour</time_frame>
    <description>Change in tear film score</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tear Film</measure>
    <time_frame>2 weeks</time_frame>
    <description>Change in tear film score</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tear Film</measure>
    <time_frame>6 weeks</time_frame>
    <description>Change in tear film score</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tear Film</measure>
    <time_frame>10 weeks</time_frame>
    <description>Change in tear film score</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Conjunctival staining</measure>
    <time_frame>6</time_frame>
    <description>Change in conjunctival staining score</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Lid margin</measure>
    <time_frame>6 weeks</time_frame>
    <description>Change in lid margin abnormality score</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Lid margin</measure>
    <time_frame>10 weeks</time_frame>
    <description>Change in lid margin abnormality score</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ocular pain from Glia OSD Symptoms Questionnaire</measure>
    <time_frame>2 weeks</time_frame>
    <description>Change in ocular pain score</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ocular pain from Glia OSD Symptoms Questionnaire</measure>
    <time_frame>10 weeks</time_frame>
    <description>Change in ocular pain score</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ocular pain from Glia OSD Symptoms Questionnaire</measure>
    <time_frame>6 weeks</time_frame>
    <description>Change in ocular pain score</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ocular discomfort</measure>
    <time_frame>6 weeks</time_frame>
    <description>Change in ocular discomfort score</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ocular discomfort</measure>
    <time_frame>10 weeks</time_frame>
    <description>Change in ocular discomfort score</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Corneal fluorescein staining</measure>
    <time_frame>6 weeks</time_frame>
    <description>Change in fluorescein staining score</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>NIH Chronic GvHD Eye Score</measure>
    <time_frame>2 weeks</time_frame>
    <description>Change in eye score</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>NIH Chronic GvHD Eye Score</measure>
    <time_frame>6 weeks</time_frame>
    <description>Change in eye score</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>NIH Chronic GvHD Eye Score</measure>
    <time_frame>10 weeks</time_frame>
    <description>Change in eye score</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">33</enrollment>
  <condition>Chronic Ocular Graft-versus-host Disease</condition>
  <arm_group>
    <arm_group_label>Pro-ocular™</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Pro-ocular™ 1% topical gel applied dermally to forehead twice daily, morning and before bedtime.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Vehicle topical gel without active ingredient applied dermally to forehead twice daily, morning and before bedtime.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pro-ocular™ topical gel</intervention_name>
    <description>Topical gel for forehead dermal application</description>
    <arm_group_label>Pro-ocular™</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo topical gel</intervention_name>
    <description>Topical gel for forehead dermal application</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Male or female of any race, at least 18 years of age at Visit 1 Screening.&#xD;
&#xD;
          2. Has the diagnosis of chronic ocular GvHD.&#xD;
&#xD;
          3. Has an NIH Consensus Eye Score of at least 2.&#xD;
&#xD;
          4. On the GLIA Ocular Surface Disease Symptoms Questionnaire at Screening, has ocular&#xD;
             discomfort at a severity score of moderate or more, and at least one other symptom at&#xD;
             a severity of moderate or more.&#xD;
&#xD;
          5. One or more signs from the list of chronic ocular GvHD signs below&#xD;
&#xD;
          6. Has provided verbal and written informed consent.&#xD;
&#xD;
          7. Be able and willing to follow oral and written instructions, including participation&#xD;
             in all study assessments and visits.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Wearing scleral or contact lenses within the last month, or those who plan to start&#xD;
             wearing scleral or contact lenses during the study.&#xD;
&#xD;
          2. Anticipate major changes in systemic GvHD management during study period.&#xD;
&#xD;
          3. Comorbidity with other severe or chronic eye conditions that in the judgment of the&#xD;
             investigator will interfere with study assessments, such as but not limited to retinal&#xD;
             detachment, recent ocular surgery, Bell's palsy, active trigeminal neuritis or&#xD;
             trigeminal neuralgia.&#xD;
&#xD;
          4. Anticipate change of vision correction or anticipate any ocular procedures during&#xD;
             study period.&#xD;
&#xD;
          5. A woman who is pregnant, nursing an infant, or planning a pregnancy.&#xD;
&#xD;
          6. A woman of childbearing potential who has a positive urine pregnancy test at Visit 1,&#xD;
             or who does not use an adequate method of birth control throughout the study period.&#xD;
&#xD;
          7. Has a known adverse reaction and/or sensitivity to the study drug or its components.&#xD;
&#xD;
          8. Unwilling to cease the use of sunscreen on the forehead or eye area.&#xD;
&#xD;
          9. Intraocular pressure &gt;22 mm Hg at screening visit with or without ongoing glaucoma&#xD;
             treatment.&#xD;
&#xD;
         10. Currently enrolled in an investigational drug or device study for chronic ocular GvHD.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Zhonghui K Luo, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Massachusetts Eye and Ear, Longwood</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Massachusetts Eye and Ear Longwood</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>June 11, 2019</study_first_submitted>
  <study_first_submitted_qc>June 15, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">June 18, 2019</study_first_posted>
  <last_update_submitted>March 12, 2021</last_update_submitted>
  <last_update_submitted_qc>March 12, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 16, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Graft vs Host Disease</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>Data may be shared with other investigators if Phase 3 study follows.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

